KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Encompass Health (EHC) EBITDA: 2009-2025

Historic EBITDA for Encompass Health (EHC) over the last 17 years, with Q3 2025 value amounting to $12.5 million.

  • Encompass Health's EBITDA fell 9150.24% to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $418.5 million, marking a year-over-year decrease of 2411.6%. This contributed to the annual value of $596.6 million for FY2024, which is 2885.53% up from last year.
  • Latest data reveals that Encompass Health reported EBITDA of $12.5 million as of Q3 2025, which was down 9150.24% from $45.3 million recorded in Q2 2025.
  • In the past 5 years, Encompass Health's EBITDA ranged from a high of $196.5 million in Q1 2025 and a low of $12.5 million during Q3 2025
  • Over the past 5 years, Encompass Health's median EBITDA value was $117.5 million (recorded in 2022), while the average stood at $115.6 million.
  • In the last 5 years, Encompass Health's EBITDA surged by 32388.06% in 2021 and then plummeted by 9150.24% in 2025.
  • Encompass Health's EBITDA (Quarter) stood at $115.7 million in 2021, then grew by 1.56% to $117.5 million in 2022, then grew by 1.36% to $119.1 million in 2023, then surged by 37.87% to $164.2 million in 2024, then crashed by 92.39% to $12.5 million in 2025.
  • Its last three reported values are $12.5 million in Q3 2025, $45.3 million for Q2 2025, and $196.5 million during Q1 2025.